Egalet Corp (NASDAQ:EGLT) shares are rising 21% after the specialty pharma company gained a tentative nod from the FDA for an expanded label …
Investors love biotech stocks for the lottery ticket-like returns they can offer if a company strikes medical gold or wins the regulator’s bless. …
Mizuho’s Irina Rivkind reflects on how much Teva’s cost cutting compare to expectations; The missing puzzle piece – revenue guidance.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced this morning the exclusive US launch of Viread®1 (tenofovir disoproxil fumarate) tablets 300 mg, a generic …
Mizuho’s Irina Rivkind Koffler cannot “justify” changing her rating on Valeant. Instead, the analyst lifts her price target by 40%; Here’s why.
Though Yescarta launch has seen patients condemned to waiting lists, Maxim’s Jason Kolbert is “inspired” by GILD’s global plan to commercialize the drug.
Cost cutting is great, but the benefits have been quickly priced into the stock.
J.P.
Why this Wall Street hedge fund legend sold VRX and GILD?
